Scarica l'app Stockscreener
2.20
5.26%
0.11
Dopo l'orario di chiusura:
2.03
-0.17
-7.73%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GANX Giù?
Forum
Previsione
Precedente Chiudi:
$2.09
Aprire:
$2.1
Volume 24 ore:
265.78K
Relative Volume:
1.09
Capitalizzazione di mercato:
$57.82M
Reddito:
$210.70K
Utile/perdita netta:
$-21.37M
Rapporto P/E:
-2.00
EPS:
-1.1
Flusso di cassa netto:
$-21.10M
1 W Prestazione:
-1.35%
1M Prestazione:
+0.92%
6M Prestazione:
+98.20%
1 anno Prestazione:
-43.15%
Intervallo 1D:
$2.045
$2.26
Intervallo di 1 settimana:
$1.96
$2.30
Portata 52W:
$0.89
$5.33
Gain Therapeutics Inc Stock (GANX) Company Profile
Nome
Gain Therapeutics Inc
Settore
Industria
Telefono
(301) 500-1556
Indirizzo
4800 HAMPDEN LANE, BETHESDA
Confronta GANX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
2.20 | 57.82M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-08-14 | Ripresa | Oppenheimer | Outperform |
| 2021-04-12 | Iniziato | BTIG Research | Buy |
| 2021-04-12 | Iniziato | Oppenheimer | Outperform |
Gain Therapeutics Inc Borsa (GANX) Ultime notizie
UiPath Inc (PATH) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Medicare Advantage Members Gain Access to Innovative Digital Therapeutics Through New Partnership - PR Newswire
This Weight-Loss Drug Stock Could Gain 200%, Challenge Novo Nordisk, Eli Lilly. - Barron's
Investors in Seres Therapeutics (NASDAQ:MCRB) from three years ago are still down 88%, even after 17% gain this past week - Simply Wall St
Vir, Sana gain new modality POC: BioCentury’s Clinical Report - BioCentury
Improved Revenues Required Before Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock's 30% Jump Looks Justified - Simply Wall St
Will CRL Stock Gain From Integration of Akron Bio's CSS Product Line? - Yahoo Finance
Perrigo cut to Hold at Argus on topline risks - MSN
Regions Financial Q4 2024 Earnings Preview - MSN
All You Need to Know About Gain Therapeutics (GANX) Rating Upgrade to Strong Buy - MSN
Gain Therapeutics regains compliance with Nasdaq listing By Investing.com - Investing.com South Africa
Gain Therapeutics regains compliance with Nasdaq listing - Investing.com India
Parkinson's Disease Clinical and Non-Clinical Studies, Key - openPR
Stock market today: Eterna Therapeutics gain over 136.63% while Phio Pharmaceuticals plunged by 40.25% in early trading - Business Upturn
Stock market news: Eterna Therapeutics posted gain of 100.87% while Phio Pharmaceuticals saw loss of 50.44% during mid day trading - Business Upturn
Geode Capital Management LLC Has $484,000 Stock Holdings in Gain Therapeutics, Inc. (NASDAQ:GANX) - Defense World
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
Coinbase Global Inc (COIN) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Best Momentum Stocks to Buy for January 9th - Yahoo Finance
Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287 - The Manila Times
Gain Therapeutics Forms Elite Advisory Board to Accelerate Parkinson's Drug Development - StockTitan
Gain Therapeutics (GANX) Shares Rise In After-Hour Trading - Stocks Telegraph
Gain Therapeutics Appoints New CEO Amidst Clinical Progress - TipRanks
Gain Therapeutics Appoints Gene Mack as Chief Executive Officer - Marketscreener.com
Gain Therapeutics appoints new CEO and finance SVP - Investing.com
Gain Therapeutics Appoints Gene Mack as CEO - citybiz
Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director - The Manila Times
Gain Therapeutics Names Gene Mack as CEO, Advancing Parkinson's Disease Drug Development - StockTitan
Viking Therapeutics, Inc. (VKTX) Stock Sinks As Market Gains: What You Should Know - MSN
Drug Innovator Launches Pivotal Cancer Trial Breakthrough - Streetwise Reports
Miami Biopharma Sells Part of Business & Begins New Clinical Trial - Streetwise Reports
Tarsus PharmaceuticalEye Care Therapeutics - TradingView
Gold just saw its biggest yearly gain since 2010 — here's why Wall Street says prices will go even higher - Yahoo Finance
Analyst Sees Major Growth for Biopharma With Weight-Loss Drug - Streetwise Reports
Gain Therapeutics: Parkinson's Drug Candidate GT-02287 Keeps Racking Up Good Results - Seeking Alpha
Analyst Initiates Coverage of Co. With 'Once-in-a-Generation' Drug - Streetwise Reports
Parkinson's Treatment Advancements: Clinical Trials Begin for Potential New Therapy - Streetwise Reports
Viking Therapeutics, Inc. (VKTX) Gains As Market Dips: What You Should Know - MSN
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Increase in Short Interest - MarketBeat
Protara Therapeutics, Inc. (NASDAQ:TARA) Sees Large Increase in Short Interest - MarketBeat
Maryland Biotech Gains Regulatory Approval - Streetwise Reports
Investing in Travere Therapeutics (NASDAQ:TVTX) a year ago would have delivered you a 82% gain - Yahoo Finance
Gain Therapeutics’ GT-02287 study to deliver positive findings, says Roth MKM - Yahoo Finance
Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from Roth Mkm - Defense World
Gain Therapeutics (NASDAQ:GANX) Initiates Phase 1b Clinical Trial for GT-02287 in Australia - Defense World
S&P 500, Nasdaq gain in choppy trading as most megacaps move higher - MSN
Why RAPT Therapeutics Stock Gained Over 100% On Monday? - Benzinga
Sage Therapeutics (SAGE) Surges 12.2%: Is This an Indication of Further Gains? - MSN
Gain Therapeutics Advances GT-02287 into Phase 1b Trial - TipRanks
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease - The Manila Times
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with - The Bakersfield Californian
Gain Therapeutics Inc Azioni (GANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.49%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):